Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIL-Rouge: Intensified ABVD vs PET-adapted ABVD in Advanced Hodgkin Lymphoma
NCT03159897Phase 3Completed
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Aug 2017
- Primary completion
- Nov 2021
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of doxorubicin, bleomycin, vinblastine, dacarbazine in Classical Hodgkin Lymphoma (cHL), sponsored by Fondazione Italiana Linfomi. Started Aug 2017; status: completed.
02
Drugs
doxorubicinbleomycinvinblastinedacarbazine
03
Conditions
Classical Hodgkin Lymphoma (cHL)
Beyond the preview
Go deeper on NCT03159897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03159897.